J.P. Morgan Healthcare Conference
Blaise Coleman, President & CEO
endo.com | ©2021 Endo International plc or one of its affiliates. All rights reserved |
Forward Looking Statements
This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislation. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future projects" or similar expressions are forward looking statements. Because these statements reflect our cur rent views, expectations and beliefs concerning future events, these forward looking statements involve risks and uncertainties. Although Endo believes that these forward looking statements and information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any o ther forward looking statements or information in this news release. Investors should note that many factors, as more fully described in the docum ents filed by Endo with securities regulators in the United States and Canada including under the caption "Risk Factors" in Endo's Form 10 -K, Form 10-Q and Form 8-K filings, as applicable, with the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis an d Retrieval ("SEDAR") and as otherwise enumerated herein or therein, could affect Endo's future financial results and could cause Endo's actual results to differ materially from those expressed in any forward looking statements. The forward looking statements in this presentation are qualified by these risk factors. Endo assumes no obligation to publicly update any forward looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.
2 | ©2021 Endo International plc or one of its affiliates. All rights reserved |
Endo: A Specialty Pharmaceutical Company
Branded
Pharmaceuticals
Sterile
Injectables
Generic
Pharmaceuticals
International Pharmaceuticals revenue Q3' YTD 2020 revenues of $76mn
Q3' YTD 2020 segment revenue
$557mn
$907mn
$603mn
3 | ©2021 Endo International plc or one of its affiliates. All rights reserved |
Our Vision and Mission
OUR VISION
Helping everyone we serve live their best life.
OUR MISSION
We develop and deliver life-enhancing
products through focused execution.
4 | ©2021 Endo International plc or one of its affiliates. All rights reserved |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Endo International plc published this content on 12 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 January 2021 20:09:01 UTC